Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > LPA(Gene name) > Human
  • Add your favorite
  • LPA (Gene name),
  • Apolipoprotein(a) (Protein name ),  APOA_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Feedback
  • Gene name:
    LPA;
    Protein name:
    Apolipoprotein(a)(Apo(a);Lp(a));
    Alternative:

    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Disulfide-linked to apo-B100. Binds to fibronectin and decorin.
    Function:
    Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330.
    Subcellular Location:
    N/A
    Protein Attributes:
    Sequence length:
    4548
    Sequence:
    50:
    MEHKEVVLLL | LLFLKSAAPE | QSHVVQDCYH | GDGQSYRGTY | STTVTGRTCQ | 
    100:
    AWSSMTPHQH | NRTTENYPNA | GLIMNYCRNP | DAVAAPYCYT | RDPGVRWEYC | 
    150:
    NLTQCSDAEG | TAVAPPTVTP | VPSLEAPSEQ | APTEQRPGVQ | ECYHGNGQSY | 
    200:
    RGTYSTTVTG | RTCQAWSSMT | PHSHSRTPEY | YPNAGLIMNY | CRNPDAVAAP | 
    250:
    YCYTRDPGVR | WEYCNLTQCS | DAEGTAVAPP | TVTPVPSLEA | PSEQAPTEQR | 
    300:
    PGVQECYHGN | GQSYRGTYST | TVTGRTCQAW | SSMTPHSHSR | TPEYYPNAGL | 
    350:
    IMNYCRNPDA | VAAPYCYTRD | PGVRWEYCNL | TQCSDAEGTA | VAPPTVTPVP | 
    400:
    SLEAPSEQAP | TEQRPGVQEC | YHGNGQSYRG | TYSTTVTGRT | CQAWSSMTPH | 
    450:
    SHSRTPEYYP | NAGLIMNYCR | NPDAVAAPYC | YTRDPGVRWE | YCNLTQCSDA | 
    500:
    EGTAVAPPTV | TPVPSLEAPS | EQAPTEQRPG | VQECYHGNGQ | SYRGTYSTTV | 
    550:
    TGRTCQAWSS | MTPHSHSRTP | EYYPNAGLIM | NYCRNPDAVA | APYCYTRDPG | 
    600:
    VRWEYCNLTQ | CSDAEGTAVA | PPTVTPVPSL | EAPSEQAPTE | QRPGVQECYH | 
    650:
    GNGQSYRGTY | STTVTGRTCQ | AWSSMTPHSH | SRTPEYYPNA | GLIMNYCRNP | 
    700:
    DAVAAPYCYT | RDPGVRWEYC | NLTQCSDAEG | TAVAPPTVTP | VPSLEAPSEQ | 
    750:
    APTEQRPGVQ | ECYHGNGQSY | RGTYSTTVTG | RTCQAWSSMT | PHSHSRTPEY | 
    800:
    YPNAGLIMNY | CRNPDAVAAP | YCYTRDPGVR | WEYCNLTQCS | DAEGTAVAPP | 
    850:
    TVTPVPSLEA | PSEQAPTEQR | PGVQECYHGN | GQSYRGTYST | TVTGRTCQAW | 
    900:
    SSMTPHSHSR | TPEYYPNAGL | IMNYCRNPDA | VAAPYCYTRD | PGVRWEYCNL | 
    950:
    TQCSDAEGTA | VAPPTVTPVP | SLEAPSEQAP | TEQRPGVQEC | YHGNGQSYRG | 
    1000:
    TYSTTVTGRT | CQAWSSMTPH | SHSRTPEYYP | NAGLIMNYCR | NPDAVAAPYC | 
    1050:
    YTRDPGVRWE | YCNLTQCSDA | EGTAVAPPTV | TPVPSLEAPS | EQAPTEQRPG | 
    1100:
    VQECYHGNGQ | SYRGTYSTTV | TGRTCQAWSS | MTPHSHSRTP | EYYPNAGLIM | 
    1150:
    NYCRNPDAVA | APYCYTRDPG | VRWEYCNLTQ | CSDAEGTAVA | PPTVTPVPSL | 
    1200:
    EAPSEQAPTE | QRPGVQECYH | GNGQSYRGTY | STTVTGRTCQ | AWSSMTPHSH | 
    1250:
    SRTPEYYPNA | GLIMNYCRNP | DAVAAPYCYT | RDPGVRWEYC | NLTQCSDAEG | 
    1300:
    TAVAPPTVTP | VPSLEAPSEQ | APTEQRPGVQ | ECYHGNGQSY | RGTYSTTVTG | 
    1350:
    RTCQAWSSMT | PHSHSRTPEY | YPNAGLIMNY | CRNPDAVAAP | YCYTRDPGVR | 
    1400:
    WEYCNLTQCS | DAEGTAVAPP | TVTPVPSLEA | PSEQAPTEQR | PGVQECYHGN | 
    1450:
    GQSYRGTYST | TVTGRTCQAW | SSMTPHSHSR | TPEYYPNAGL | IMNYCRNPDA | 
    1500:
    VAAPYCYTRD | PGVRWEYCNL | TQCSDAEGTA | VAPPTVTPVP | SLEAPSEQAP | 
    1550:
    TEQRPGVQEC | YHGNGQSYRG | TYSTTVTGRT | CQAWSSMTPH | SHSRTPEYYP | 
    1600:
    NAGLIMNYCR | NPDAVAAPYC | YTRDPGVRWE | YCNLTQCSDA | EGTAVAPPTV | 
    1650:
    TPVPSLEAPS | EQAPTEQRPG | VQECYHGNGQ | SYRGTYSTTV | TGRTCQAWSS | 
    1700:
    MTPHSHSRTP | EYYPNAGLIM | NYCRNPDAVA | APYCYTRDPG | VRWEYCNLTQ | 
    1750:
    CSDAEGTAVA | PPTVTPVPSL | EAPSEQAPTE | QRPGVQECYH | GNGQSYRGTY | 
    1800:
    STTVTGRTCQ | AWSSMTPHSH | SRTPEYYPNA | GLIMNYCRNP | DAVAAPYCYT | 
    1850:
    RDPGVRWEYC | NLTQCSDAEG | TAVAPPTVTP | VPSLEAPSEQ | APTEQRPGVQ | 
    1900:
    ECYHGNGQSY | RGTYSTTVTG | RTCQAWSSMT | PHSHSRTPEY | YPNAGLIMNY | 
    1950:
    CRNPDAVAAP | YCYTRDPGVR | WEYCNLTQCS | DAEGTAVAPP | TVTPVPSLEA | 
    2000:
    PSEQAPTEQR | PGVQECYHGN | GQSYRGTYST | TVTGRTCQAW | SSMTPHSHSR | 
    2050:
    TPEYYPNAGL | IMNYCRNPDA | VAAPYCYTRD | PGVRWEYCNL | TQCSDAEGTA | 
    2100:
    VAPPTVTPVP | SLEAPSEQAP | TEQRPGVQEC | YHGNGQSYRG | TYSTTVTGRT | 
    2150:
    CQAWSSMTPH | SHSRTPEYYP | NAGLIMNYCR | NPDAVAAPYC | YTRDPGVRWE | 
    2200:
    YCNLTQCSDA | EGTAVAPPTV | TPVPSLEAPS | EQAPTEQRPG | VQECYHGNGQ | 
    2250:
    SYRGTYSTTV | TGRTCQAWSS | MTPHSHSRTP | EYYPNAGLIM | NYCRNPDAVA | 
    2300:
    APYCYTRDPG | VRWEYCNLTQ | CSDAEGTAVA | PPTVTPVPSL | EAPSEQAPTE | 
    2350:
    QRPGVQECYH | GNGQSYRGTY | STTVTGRTCQ | AWSSMTPHSH | SRTPEYYPNA | 
    2400:
    GLIMNYCRNP | DAVAAPYCYT | RDPGVRWEYC | NLTQCSDAEG | TAVAPPTVTP | 
    2450:
    VPSLEAPSEQ | APTEQRPGVQ | ECYHGNGQSY | RGTYSTTVTG | RTCQAWSSMT | 
    2500:
    PHSHSRTPEY | YPNAGLIMNY | CRNPDAVAAP | YCYTRDPGVR | WEYCNLTQCS | 
    2550:
    DAEGTAVAPP | TVTPVPSLEA | PSEQAPTEQR | PGVQECYHGN | GQSYRGTYST | 
    2600:
    TVTGRTCQAW | SSMTPHSHSR | TPEYYPNAGL | IMNYCRNPDA | VAAPYCYTRD | 
    2650:
    PGVRWEYCNL | TQCSDAEGTA | VAPPTVTPVP | SLEAPSEQAP | TEQRPGVQEC | 
    2700:
    YHGNGQSYRG | TYSTTVTGRT | CQAWSSMTPH | SHSRTPEYYP | NAGLIMNYCR | 
    2750:
    NPDAVAAPYC | YTRDPGVRWE | YCNLTQCSDA | EGTAVAPPTV | TPVPSLEAPS | 
    2800:
    EQAPTEQRPG | VQECYHGNGQ | SYRGTYSTTV | TGRTCQAWSS | MTPHSHSRTP | 
    2850:
    EYYPNAGLIM | NYCRNPDAVA | APYCYTRDPG | VRWEYCNLTQ | CSDAEGTAVA | 
    2900:
    PPTVTPVPSL | EAPSEQAPTE | QRPGVQECYH | GNGQSYRGTY | STTVTGRTCQ | 
    2950:
    AWSSMTPHSH | SRTPEYYPNA | GLIMNYCRNP | DAVAAPYCYT | RDPGVRWEYC | 
    3000:
    NLTQCSDAEG | TAVAPPTVTP | VPSLEAPSEQ | APTEQRPGVQ | ECYHGNGQSY | 
    3050:
    RGTYSTTVTG | RTCQAWSSMT | PHSHSRTPEY | YPNAGLIMNY | CRNPDAVAAP | 
    3100:
    YCYTRDPGVR | WEYCNLTQCS | DAEGTAVAPP | TVTPVPSLEA | PSEQAPTEQR | 
    3150:
    PGVQECYHGN | GQSYRGTYST | TVTGRTCQAW | SSMTPHSHSR | TPEYYPNAGL | 
    3200:
    IMNYCRNPDA | VAAPYCYTRD | PGVRWEYCNL | TQCSDAEGTA | VAPPTVTPVP | 
    3250:
    SLEAPSEQAP | TEQRPGVQEC | YHGNGQSYRG | TYSTTVTGRT | CQAWSSMTPH | 
    3300:
    SHSRTPEYYP | NAGLIMNYCR | NPDAVAAPYC | YTRDPGVRWE | YCNLTQCSDA | 
    3350:
    EGTAVAPPTV | TPVPSLEAPS | EQAPTEQRPG | VQECYHGNGQ | SYRGTYSTTV | 
    3400:
    TGRTCQAWSS | MTPHSHSRTP | EYYPNAGLIM | NYCRNPDPVA | APYCYTRDPS | 
    3450:
    VRWEYCNLTQ | CSDAEGTAVA | PPTITPIPSL | EAPSEQAPTE | QRPGVQECYH | 
    3500:
    GNGQSYQGTY | FITVTGRTCQ | AWSSMTPHSH | SRTPAYYPNA | GLIKNYCRNP | 
    3550:
    DPVAAPWCYT | TDPSVRWEYC | NLTRCSDAEW | TAFVPPNVIL | APSLEAFFEQ | 
    3600:
    ALTEETPGVQ | DCYYHYGQSY | RGTYSTTVTG | RTCQAWSSMT | PHQHSRTPEN | 
    3650:
    YPNAGLTRNY | CRNPDAEIRP | WCYTMDPSVR | WEYCNLTQCL | VTESSVLATL | 
    3700:
    TVVPDPSTEA | SSEEAPTEQS | PGVQDCYHGD | GQSYRGSFST | TVTGRTCQSW | 
    3750:
    SSMTPHWHQR | TTEYYPNGGL | TRNYCRNPDA | EISPWCYTMD | PNVRWEYCNL | 
    3800:
    TQCPVTESSV | LATSTAVSEQ | APTEQSPTVQ | DCYHGDGQSY | RGSFSTTVTG | 
    3850:
    RTCQSWSSMT | PHWHQRTTEY | YPNGGLTRNY | CRNPDAEIRP | WCYTMDPSVR | 
    3900:
    WEYCNLTQCP | VMESTLLTTP | TVVPVPSTEL | PSEEAPTENS | TGVQDCYRGD | 
    3950:
    GQSYRGTLST | TITGRTCQSW | SSMTPHWHRR | IPLYYPNAGL | TRNYCRNPDA | 
    4000:
    EIRPWCYTMD | PSVRWEYCNL | TRCPVTESSV | LTTPTVAPVP | STEAPSEQAP | 
    4050:
    PEKSPVVQDC | YHGDGRSYRG | ISSTTVTGRT | CQSWSSMIPH | WHQRTPENYP | 
    4100:
    NAGLTENYCR | NPDSGKQPWC | YTTDPCVRWE | YCNLTQCSET | ESGVLETPTV | 
    4150:
    VPVPSMEAHS | EAAPTEQTPV | VRQCYHGNGQ | SYRGTFSTTV | TGRTCQSWSS | 
    4200:
    MTPHRHQRTP | ENYPNDGLTM | NYCRNPDADT | GPWCFTMDPS | IRWEYCNLTR | 
    4250:
    CSDTEGTVVA | PPTVIQVPSL | GPPSEQDCMF | GNGKGYRGKK | ATTVTGTPCQ | 
    4300:
    EWAAQEPHRH | STFIPGTNKW | AGLEKNYCRN | PDGDINGPWC | YTMNPRKLFD | 
    4350:
    YCDIPLCASS | SFDCGKPQVE | PKKCPGSIVG | GCVAHPHSWP | WQVSLRTRFG | 
    4400:
    KHFCGGTLIS | PEWVLTAAHC | LKKSSRPSSY | KVILGAHQEV | NLESHVQEIE | 
    4450:
    VSRLFLEPTQ | ADIALLKLSR | PAVITDKVMP | ACLPSPDYMV | TARTECYITG | 
    4500:
    WGETQGTFGT | GLLKEAQLLV | IENEVCNHYK | YICAEHLARG | TDSCQGDSGG | 
    4548:
    PLVCFEKDKY | ILQGVTSWGL | GCARPNKPGV | YARVSRFVTW | IEGMMRNN
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    MIM:
    String:
    UniGene:
    Pfam:
    KEGG:
    Uniprot:
     
    FOR
    ELISA Kit for Human Apo(a)
    Cat.:
    E0842h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Apo(a)
    Cat.:
    U0842h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Polyclonal Antibody for Human Apo(a)
    Cat.:
    P0842Rb-h
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Monoclonal Antibody for Human Apo(a)
    Protein for Human Apo(a)

    R&D Technical Data
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤5.6%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤9.3%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery

    Recovery was determined by spiking various levels of Apo(a) into serum and plasma .

    Sample Type

    Average(%)

    Recovery  Range (%)

    Serum

    95

    89-102

    Plasma

    98

    90-105

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration ofApo(a) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    88-99%                 

    89-104%

    91-105%

    83-99%

    EDTA plasma(n=5)

    79-99%

    85-97%

    93-106%

    87-98%

    heparin plasma(n=5)

    84-101%

     

    89-104%

    91-102%

    91-104%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen."
      McLean J.W. , Tomlison J.E. , Kuang W.-J. , Eaton D.L. , Chen E.Y. , Fless G.M. , Scanu A.M. , Lawn R.M.
      Nature330:132-137(1987) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA];POLYMORPHISM
    2. 2.
      "The DNA sequence and analysis of human chromosome 6."
      Mungall A.J. , Palmer S.A. , Sims S.K. , Edwards C.A. , Ashurst J.L. , Wilming L. , Jones M.C. , Horton R. , Hunt S.E. , Scott C.E. , Gilbert J.G.R. , Clamp M.E. , Bethel G. , Milne S. , Ainscough R. , Almeida J.P. , Ambrose K.D. , Andrews T.D. , more...
      Nature425:805-811(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    3. 3.
      "Amplification of human APO(a) kringle 4-37 from blood lymphocyte DNA."
      Pfaffinger D. , Mc Lean J. , Scanu A.M.
      Biochim. Biophys. Acta1225:107-109(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 4184-4208
      tissue: Lymphocyte.
    4. 4.
      "Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it."
      Salonen E.-M. , Jauhiainen M. , Zardi L. , Vaheri A. , Ehnholm C.
      EMBO J.8:4035-4040(1989) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION AS A SERINE PROTEASE
    5. 5.
      "The mysteries of lipoprotein(a)."
      Utermann G.
      Science246:904-910(1989) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: REVIEW
    6. 6.
      "Structural elucidation of the N- and O-glycans of human apolipoprotein(a): role of o-glycans in conferring protease resistance."
      Garner B. , Merry A.H. , Royle L. , Harvey D.J. , Rudd P.M. , Thillet J.
      J. Biol. Chem.276:22200-22208(2001) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: STRUCTURE OF N-LINKED AND O-LINKED CARBOHYDRATES;IDENTIFICATION BY MASS SPECTROMETRY
    7. 7.
      "Crystal structures of apolipoprotein(a) kringle IV37 free and complexed with 6-aminohexanoic acid and with p-aminomethylbenzoic acid: existence of novel and expected binding modes."
      Mikol V. , Lograsso P.V. , Boettcher B.R.
      J. Mol. Biol.256:751-761(1996) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 4121-4208
    8. 8.
      "A single point mutation (Trp72-->Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a)."
      Scanu A.M. , Pfaffinger D. , Lee J.C. , Hinman J.
      Biochim. Biophys. Acta1227:41-45(1994) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT ARG-4193
    Product Feedback Wall
    Hot Genes
    Atf2 ASPRO ACE ALCAM C19orf80 Trap1a KSR2 Gdf5
    Top Searches
    Ubiquitin-protein ligase metalloproteinase Ubiquitin ELISA Tumor necrosis Asprosin TRAP1A Alpha
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.com.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    Twitter